BeiGene · 9 hours ago
Intern - Regulatory Affairs, CMC (year-round)
Maximize your interview chances
BiotechnologyHealth Care
No H1B
Insider Connection @BeiGene
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Updated and maintain accurate CMC information in the BeiGene Regulatory Information Management system
Data remediation
Creation and maintenance of CMC Submission Content
Uploading HA Correspondence/HA Questions/Commitments
Maintain internal Regulatory CMC trackers
Contribute to Regulatory CMC process improvements
Support the drafting of CTD CMC sections to ensure on-time and high-quality global applications for direct submission to Health Authorities as needed
Provide support to Regulatory CMC team or hiring manager with Regulatory submissions and other tasks as needed
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Active enrollment (Graduate or Ph.D.) in an accredited college or university pursuing a degree in a scientific discipline (e.g., life sciences, chemistry, biology, biotechnology, materials science, etc.) with a minimum 3.0 GPA
Proficient in Microsoft Office
Legally authorized to work in the United States without needing sponsorship for employment now or in the future
Ability to work independently on assignments with routine check-ins
Strong written and oral communication skills
Organized, responsible, resourceful, and detail-oriented
Able to work in a cross-cultural team environment
Able to work remotely using MS TEAMS and other collaboration tools
Preferred
Awareness of processes for working in a regulated field
Basic knowledge of healthcare industry and strong passion for biotech
Benefits
Medical
Dental
Vision
401(k)
FSA/HSA
Life Insurance
Paid Time Off
Wellness
Company
BeiGene
BeiGene is a global oncology company.
Funding
Current Stage
Public CompanyTotal Funding
$6.79BKey Investors
Hillhouse InvestmentAmgen
2020-07-12Post Ipo Equity· $2.08B
2019-10-31Post Ipo Equity· $2.7B
2018-08-02Post Ipo Secondary· $903M
Recent News
2024-12-17
2024-12-17
2024-12-17
Company data provided by crunchbase